Please assess the completion status of the following clinical trial:

Trial Title: Study of LJP 394 in Lupus Patients With History of Renal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Systemic Lupus Erythematosus (SLE)~* Active SLE renal disease within past 4 years.~* Males or females between 12 and 70 years old.~* Females must be non-pregnant and non-lactating. Females and males must use adequate birth control methods during course of study.~* Ability to have weekly intravenous (IV) administration of study treatment.~Exclusion Criteria:~* Active SLE renal disease within past 3 months prior to entering study.~* Use of the following therapies within 3 months prior to entering the study: alkylating agents, e.g., cyclophosphamide, TNF inhibitors, cyclosporine.~* Use of mycophenolate mofetil that exceeds 1000 mg/day, azathioprine that exceeds 100 mg/day, methotrexate that exceeds 10 mg/week, leflunomide that exceeds 10 mg/day within 2 months prior to entering study.~* Use of rituximab within 6 months prior to entering study.~* Current abuse of drugs or alcohol.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
- 2 (Type: ACTIVE_COMPARATOR): 900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
- 3 (Type: PLACEBO_COMPARATOR): A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).